Cholinesterase inhibition for Alzheimer disease - A meta-analysis of the tacrine trials

被引:120
作者
Qizilbash, N [1 ]
Whitehead, A
Higgins, J
Wilcock, G
Schneider, L
Farlow, M
机构
[1] Univ Oxford, Radcliffe Infirm, Dept Clin Geratol, Cochrane Dementia Grp,Dementia Trialists Collabor, Oxford OX2 6HE, England
[2] Univ Reading, MPS Res Unit, Reading RG6 2AH, Berks, England
[3] Inst Child Hlth, Systemat Reviews TRaining Unit, London, England
[4] Frenchay Hosp, Dept Care Elderly, Bristol BS16 1LE, Avon, England
[5] Univ So Calif, Sch Med, Dept Psychiat, Los Angeles, CA USA
[6] Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1998年 / 280卷 / 20期
关键词
D O I
10.1001/jama.280.20.1777
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives.-To determine the effects of cholinesterase inhibition with tacrine hydrochloride for the symptoms of Alzheimer disease in terms of cognitive performance, clinical global impression, behavior, and functional autonomy. Data Sources.-The Cochrane Dementia Group registry of trials. Study Selection.-Unconfounded, randomized, double-blind, placebo-controlled trials in which tacrine had been given for more than 1 day and that were completed before January 1, 1996. Data Extraction.-Two reviewers independently selected trials for inclusion and individual patient data were sought. Data Synthesis.-Data were analyzed from 12 trials that included 1984 patients with Alzheimer disease. At 12 weeks, cognitive performance, as measured by the Mini-Mental State Examination (score range, 0-30), was better in patients receiving tacrine than in patients receiving placebo by 0.62 points (95% confidence interval [CI], 0.23-1.00; P = .002). Compared with similar untreated patients who would be expected to deteriorate by 0.50 to 1.00 points on the Mini-Mental State Examination during 12 weeks, the progress of patients receiving tacrine would be expected to range between an improvement of 0.12 and a deterioration of 0.38 points. The odds ratio for improvement on the Clinical Global Impression of Change scale (range, 1-7) for patients receiving tacrine compared with those receiving placebo was 1.58 (95% CI, 1.18-2.1 1; P = .002). The behavioral noncognitive subscale of the Alzheimer's Disease Assessment Scale (range, 0-50) showed a difference in favor of tacrine of 0.58 points (95% CI, 0.17-1.00; P = .006). Improvement on the Progressive Deterioration Scale, largely an index of functional activities, was not significant (0.75; 95% CI, -0.43 to 1.93; P = .21). Age, severity of dementia, and exposure to tacrine prior to randomization had no clear influence on the treatment effect. There was a nonsignificant trend toward increasing effect with increasing dose for cognitive function and the Clinical Global impression of Change. For patients without prior exposure to tacrine, the odds of patients' withdrawing during the study while they were receiving tacrine compared with placebo was 3.63 (95% CI, 2.80-4.71; P < .001). Eleven (95% CI, 7-31) patients would need to be treated to achieve any improvement on the Clinical Global Impression scale, and 42 (95% CI, 23-125) to achieve a moderate or marked improvement. One patient would be expected to withdraw for every 4 (95% CI, 3-5) patients treated. Conclusions.-Cholinesterase inhibition with tacrine appears to reduce deterioration in cognitive performance during the first 3 months and increase the odds of global clinical improvement. Effects observed on measures of behavioral disturbance were of questionable clinical significance, and functional autonomy was not significantly affected. The clinical relevance of the benefits of cholinesterase inhibition remains controversial, and long-term trials with clinically relevant end points are required.
引用
收藏
页码:1777 / 1782
页数:6
相关论文
共 34 条
  • [1] TACRINE (TETRAHYDROAMINOACRIDINE - THA) AND LECITHIN IN SENILE DEMENTIA OF THE ALZHEIMER TYPE - A MULTICENTER TRIAL
    CHATELLIER, G
    LACOMBLEZ, L
    [J]. BRITISH MEDICAL JOURNAL, 1990, 300 (6723) : 495 - 499
  • [2] TETRAHYDROAMINOACRIDINE IN ALZHEIMERS-DISEASE
    DAVIES, B
    ANDREWES, D
    STARGATT, R
    AMES, D
    TUCKWELL, V
    DAVIS, S
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 1990, 5 (05) : 317 - 321
  • [3] A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF TACRINE FOR ALZHEIMERS-DISEASE
    DAVIS, KL
    THAL, LJ
    GAMZU, ER
    DAVIS, CS
    WOOLSON, RF
    GRACON, SI
    DRACHMAN, DA
    SCHNEIDER, LS
    WHITEHOUSE, PJ
    HOOVER, TM
    MORRIS, JC
    KAWAS, CH
    KNOPMAN, DS
    EARL, NL
    KUMAR, V
    DOODY, RS
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (18) : 1253 - 1259
  • [4] TACRINE
    DAVIS, KL
    POWCHIK, P
    [J]. LANCET, 1995, 345 (8950) : 625 - 630
  • [5] DEJONG R, 1989, CLIN THER, V11, P545
  • [6] SERUM LEVELS OF TACRINE IN RELATION TO CLINICAL-RESPONSE IN ALZHEIMERS-DISEASE
    EAGGER, S
    LEVY, R
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 1992, 7 (02) : 115 - 119
  • [7] A CONTROLLED TRIAL OF TACRINE IN ALZHEIMERS-DISEASE
    FARLOW, M
    GRACON, SI
    HERSHEY, LA
    LEWIS, KW
    SADOWSKY, CH
    DOLANURENO, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (18): : 2523 - 2529
  • [8] FARLOW MR, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P283
  • [9] Ferris SH, 1997, ALZ DIS ASSOC DIS, V11, pS1
  • [10] FITTEN LJ, 1990, AM J PSYCHIAT, V147, P239